MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of shares...
Stock-based compensation
Accounts payable, accrued expens...
Others
Negative Cash Flow Breakdown
Net loss
Payments on short-term financing...
Repayments of notes payable
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-4,807
-14,455
-5,298
-6,400
Stock-based compensation
711
305
471
685
Issuance of shares for services
-
-
0
0
Accretion of debt issuance costs on convertible notes payable
10
10
496
93
Gain on settlement of current liabilities
0
167
966
774
Loss on debt extinguishment
-
-
-2,197
-967
Change in fair value of warrant liabilities
-99
44
442
253
Impairment loss on other intangible assets
0
3,700
0
5,180
Impairment loss on goodwill
0
8,430
-
-
Loss on derivative liability
-
-
-130
-100
Change in fair value of derivative liability
0
230
-
-
Deferred tax benefit
0
-859
0
-1,088
Unrealized foreign currency exchange gains
-63
15
-351
56
Prepaid expenses and other current assets
-192
94
-202
-129
Accounts payable, accrued expenses and other current liabilities
623
931
-182
-704
Net cash used in operating activities
-3,109
-2,488
-3,041
-2,121
Proceeds from issuance of shares, net of issuance costs
-
-
4,846
0
Proceeds from issuance of notes payable
-
-
0
2,099
Repayment of notes payable and convertible notes
-
-
553
-
Proceeds from employee vesting of restricted shares
-
-
0
0
Proceeds from issuance of warrants
-
-
706
0
Proceeds from issuance of shares, net of issuance costs
8,238
188
-
-
Proceeds from pre-funded warrants
-
-
330
-
Repayments of notes payable
-48
455
-
-33
Payments on short-term financing arrangement
155
102
57
169
Net cash provided by financing activities
8,035
53
5,760
1,897
Effect of exchange rates on cash
-
-
0
-3
Net change in cash
4,926
-2,435
2,719
-227
Cash and restricted cash at beginning of period
2,828
5,263
2,544
2,659
Cash and restricted cash at end of period
7,754
2,828
5,263
2,544
Cash
7,694
-
-
-
Restricted cash
60
-
-
-
Total cash and restricted cash
7,754
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
shares, net of issuance...
$8,238K
(40.13%↑ Y/Y)
Net cash provided by
financing activities
$8,035K
(45.72%↑ Y/Y)
Canceled cashflow
$203K
Net change in cash
$4,926K
(4298.21%↑ Y/Y)
Canceled cashflow
$3,109K
Payments on short-term
financing arrangement
$155K
(-43.22%↓ Y/Y)
Repayments of notes payable
-$48K
(89.45%↑ Y/Y)
Stock-based compensation
$711K
(-59.00%↓ Y/Y)
Accounts payable,
accrued expenses and...
$623K
(656.25%↑ Y/Y)
Prepaid expenses and
other current assets
-$192K
(27.00%↑ Y/Y)
Change in fair value of
warrant liabilities
-$99K
(-223.75%↓ Y/Y)
Unrealized foreign
currency exchange gains
-$63K
(-115.99%↓ Y/Y)
Accretion of debt issuance
costs on convertible...
$10K
Net cash used in
operating activities
-$3,109K
(42.49%↑ Y/Y)
Canceled cashflow
$1,698K
Net loss
-$4,807K
(14.16%↑ Y/Y)
Buy us a coffee
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)